Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study

GLP-1 receptor agonist use was associated with lower odds of undergoing neurosurgical interventions in idiopathic intracranial hypertension patients.

• Patients receiving GLP-1 receptor agonists had a 2.40 times lower likelihood of needing venous sinus stenting at 5 weeks compared to untreated controls.
• At 6 months, the odds of requiring venous sinus stenting remained significantly lower (OR 2.31) for those on GLP-1 receptor agonists.
• GLP-1 receptor agonist therapy was linked to a 3.34 times reduction in the odds of needing ventriculoperitoneal shunting at 5 weeks.
• The likelihood of undergoing ventriculoperitoneal shunting was also significantly lower at 6 months (OR 2.51) for patients treated with GLP-1 receptor agonists.

AI simplified